Chiaki Tao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiaki Tao has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Laurent Casanova
University of Texas Southwestern 1 Laboratory of Human Genetics of Infectious Diseases Dallas, TX
2 shared publications - Paul Bastard
Necker Branch, INSERM UMR 1163 3 Laboratory of Human Genetics of Infectious Diseases, Institut Imagine, Université Paris Cité Paris
2 shared publications - Satoshi Okada
Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
2 shared publications - Anne Puel
Necker Branch, INSERM UMR 1163 3 Laboratory of Human Genetics of Infectious Diseases, Institut Imagine, Université Paris Cité Paris
1 shared publication - Aurélie Cobat
Necker Branch, INSERM UMR 1163 3 Laboratory of Human Genetics of Infectious Diseases, Institut Imagine, Université Paris Cité Paris
1 shared publication - Bettina Bundgaard
Aarhus University 1 Department of Biomedicine Aarhus
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
The rise in prevalence of autoantibodies neutralizing type I interferons reaches a plateau in centenarians
While autoantibodies (auto-Abs) neutralizing type I interferons (IFN-I) are relatively rare before the age of 65 (6% in individuals above 80 years in the general population. To assess the prevalence of IFN-I auto-Abs at the extreme end of human lifespan, we performed a multinational study of centenarians from four geographically and ethnically distinct cohorts collected in Denmark (n = 258), Colombia (n = 99), Australia (n = 281), and Japan (n = 300), comprising 938 individuals. Across cohorts, 51/938 centenarians (5.4%) harbored auto-Abs neutralizing IFN-I, ranging from 3.3% (Japan) to 9.1% (Colombia). We found that the prevalence of IFN-I auto-Abs levels off in centenarians compared with individuals ≥80 years from the general population, demonstrating that neutralizing IFN-I auto-Abs are not incompatible with longevity, despite conferring a risk of life-threatening viral infections. Yet, the plateau of their prevalence in centenarians suggests that they may not be beneficial for reaching exceptional longevity and may negatively impact mortality.
- 27 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Open AccessThe rise in prevalence of autoantibodies neutralizing type I interferons reaches a plateau in centenarians
While autoantibodies (auto-Abs) neutralizing type I interferons (IFN-I) are relatively rare before the age of 65 (6% in individuals above 80 years in the general population. To assess the prevalence of IFN-I auto-Abs at the extreme end of human lifespan, we performed a multinational study of centenarians from four geographically and ethnically distinct cohorts collected in Denmark (n = 258), Colombia (n = 99), Australia (n = 281), and Japan (n = 300), comprising 938 individuals. Across cohorts, 51/938 centenarians (5.4%) harbored auto-Abs neutralizing IFN-I, ranging from 3.3% (Japan) to 9.1% (Colombia). We found that the prevalence of IFN-I auto-Abs levels off in centenarians compared with individuals ≥80 years from the general population, demonstrating that neutralizing IFN-I auto-Abs are not incompatible with longevity, despite conferring a risk of life-threatening viral infections. Yet, the plateau of their prevalence in centenarians suggests that they may not be beneficial for reaching exceptional longevity and may negatively impact mortality.
- Open Access
- 16 September 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C
Autoantibodies neutralizing type I IFNs (AAN-I-IFNs) are being identified as major, common, and global determinants of a growing range of severe viral diseases. We examined whether persistent hepatitis C virus (HCV) infection, with or without IFN-α therapy, could induce AAN-I-IFNs. We tested 2,573 HCV patients aged 1–95 years (1,115 treated with IFN-α, 1,458 untreated) and 1,000 healthy controls. AAN-INF-α2 prevalence was significantly higher in hepatitis C patients (2.7%) than in healthy controls (0.7%) and was higher still in those treated with IFN-α (3.9%) than in untreated patients (1.9%) (P = 0.0053). A longitudinal study of 15 IFN-α–treated patients with AAN-IFN-α2 revealed that only one had AAN-IFN-α2 before IFN-α therapy and that 12 patients developed AAN-IFN-α2 in the year following treatment. However, 80% eventually became AAN-IFN-α2 negative. These findings suggest that chronic HCV infection, perhaps due to the chronic production of endogenous IFN-α, and exogenous IFN-α treatment promote the development of AAN-IFN-α2.
- 16 September 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Open AccessHigh prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C
Autoantibodies neutralizing type I IFNs (AAN-I-IFNs) are being identified as major, common, and global determinants of a growing range of severe viral diseases. We examined whether persistent hepatitis C virus (HCV) infection, with or without IFN-α therapy, could induce AAN-I-IFNs. We tested 2,573 HCV patients aged 1–95 years (1,115 treated with IFN-α, 1,458 untreated) and 1,000 healthy controls. AAN-INF-α2 prevalence was significantly higher in hepatitis C patients (2.7%) than in healthy controls (0.7%) and was higher still in those treated with IFN-α (3.9%) than in untreated patients (1.9%) (P = 0.0053). A longitudinal study of 15 IFN-α–treated patients with AAN-IFN-α2 revealed that only one had AAN-IFN-α2 before IFN-α therapy and that 12 patients developed AAN-IFN-α2 in the year following treatment. However, 80% eventually became AAN-IFN-α2 negative. These findings suggest that chronic HCV infection, perhaps due to the chronic production of endogenous IFN-α, and exogenous IFN-α treatment promote the development of AAN-IFN-α2.
- 2 July 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (9) , e31891
Concurrent Immune Thrombocytopenia and Autoimmune Neutropenia in a 4‐Year‐Old Male Patient With XIAP Deficiency: A Case Report
- 2 July 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (9) , e31891
Concurrent Immune Thrombocytopenia and Autoimmune Neutropenia in a 4‐Year‐Old Male Patient With XIAP Deficiency: A Case Report
- 6 December 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (3) , 102579
Antibody titer trends after SARS-CoV-2 vaccination in patients aged 12–25 years with underlying diseases
- 6 December 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (3) , 102579
Antibody titer trends after SARS-CoV-2 vaccination in patients aged 12–25 years with underlying diseases